CHUC Charlie's (CHUC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001134765
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Charlie's insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Charlie's Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 1, 2002.
- The trade is 10.6% of the 2,351,968 shares held after it.
- 4 other insiders bought within 30 days.
Insider activity: Chief Operating Officer Stump Ryan bought about $50.0K of CHUC on Feb 13, 2026, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 17, 2025.
- -4.1% median (-4.1% mean) 90-day return after 2 previous buys.
- The trade is 2.5% of the 9,850,001 shares held after it.
- 4 other insiders bought within 30 days.
Insider activity: President SICIGNANO HENRY III bought about $50.0K of CHUC on Feb 13, 2026, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 29, 2022.
- The trade is 3.5% of the 2,825,409 shares held after it.
- 4 other insiders bought within 30 days.
Insider activity: Chief Financial Officer Montesano Matthew P bought about $20.0K of CHUC on Feb 13, 2026; 4 other insiders bought within 30 days.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 31, 2024.
- The trade is 7.4% of the 6,750,001 shares held after it.
- 4 other insiders bought within 30 days.
Insider activity: Director King Michael D bought about $100.0K of CHUC on Feb 13, 2026, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Dec 26, 2025.
- -33.7% median (-17.1% mean) 90-day return after 8 previous buys.
- The trade is 11.6% of the 2,156,481 shares held after it.
- 4 other insiders bought within 30 days.
Insider activity: Director Carmines Edward bought about $50.0K of CHUC on Feb 13, 2026, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days.18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+169.4% year over year
more than 88% of Pharma & Biotech
Margin
21.5% net margin
more than 88% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 95% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CHUC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-42.3%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CHUC: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in CHUC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CHUC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Henry Sicignano III
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$277.7K
$451.6K
$211.1K
+179%
n/a
2024
$242.8K
$201.2K
$188.1K
-50%
n/a
2023
$323.0K
$373.0K
$242.0K
+6%
n/a
2022
$270.0K
$242.0K
$376.0K
-61%
n/a
2021
$218.0K
$230.0K
$311.0K
-60%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
CHUC financials
Revenue growth
+169.4%
XBRL, annual
Net margin
21.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$24.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CHUC
| FY Dec 2025 | $20.9M |
| FY Dec 2024 | $8.5M |
| FY Dec 2023 | $16.2M |
| FY Dec 2022 | $26.4M |
| FY Dec 2021 | $21.5M |
| Jun 2026 | $3.8M |
| Mar 2026 | $4.8M |
| Dec 2025 | $9.0M |
| Sep 2025 | $7.1M |
| Jun 2025 | $2.5M |
| Mar 2025 | $2.3M |
| Dec 2024 | $1.8M |
| Sep 2024 | $1.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-7.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CHUC
| FY Dec 2025 | +21.5% |
| FY Dec 2024 | -49.0% |
| FY Dec 2023 | -12.9% |
| FY Dec 2022 | -6.0% |
| FY Dec 2021 | +22.4% |
| Jun 2026 | -43.7% |
| Mar 2026 | -21.9% |
| Dec 2025 | +1.5% |
| Sep 2025 | +8.8% |
| Jun 2025 | +195.0% |
| Mar 2025 | -52.8% |
| Dec 2024 | -63.3% |
| Sep 2024 | -62.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$4.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CHUC
| FY Dec 2025 | -$5.8M |
| FY Dec 2024 | -$1.6M |
| FY Dec 2023 | -$783.0K |
| FY Dec 2022 | -$1.9M |
| FY Dec 2021 | -$1.5M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
2.08x
long-term 2025-03-31 (15 months older than the period end) plus current 2019-03-31 (88 months older than the period end); equity 2026-06-30
Debt to equity CHUC
| FY Dec 2025 | 1.91x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 2.85x |
| FY Dec 2021 | 1.13x |
| Jun 2026 | 2.08x |
| Mar 2026 | 2.10x |
| Dec 2025 | 1.91x |
| Sep 2025 | 2.02x |
| Jun 2025 | 2.98x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.64x
TTM operating cash flow over long-term 2025-03-31 (15 months older than the period end) plus current 2019-03-31 (88 months older than the period end)
Cash flow to debt CHUC
| FY Dec 2025 | -0.88x |
| FY Dec 2024 | -0.29x |
| FY Dec 2023 | -0.13x |
| FY Dec 2022 | -0.36x |
| FY Dec 2021 | -0.38x |
| Jun 2026 | -0.64x |
| Mar 2026 | -0.99x |
| Dec 2025 | -0.88x |
| Sep 2025 | -1.00x |
| Jun 2025 | -0.67x |
| Mar 2025 | -0.24x |
| Dec 2024 | -0.29x |
| Sep 2024 | -0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-73.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CHUC
| FY Dec 2025 | +547.7% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -262.8% |
| FY Dec 2022 | -65.9% |
| FY Dec 2021 | n/a |
| Jun 2026 | -73.5% |
| Mar 2026 | +3,121% |
| Dec 2025 | +547.7% |
| Sep 2025 | +328.1% |
| Jun 2025 | +168.6% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-20.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CHUC
| FY Dec 2025 | +58.0% |
| FY Dec 2024 | -85.6% |
| FY Dec 2023 | -32.6% |
| FY Dec 2022 | -19.5% |
| FY Dec 2021 | +61.0% |
| Jun 2026 | -20.9% |
| Mar 2026 | +51.8% |
| Dec 2025 | +58.0% |
| Sep 2025 | +43.9% |
| Jun 2025 | +28.5% |
| Mar 2025 | -109.6% |
| Dec 2024 | -85.6% |
| Sep 2024 | -56.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital CHUC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -34.8% |
| Jun 2025 | -37.6% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed CHUC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -133.8% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -217.8% |
| Jun 2025 | -315.4% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CHUC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$48.6M
market value at close 2026-10-27 on 2026-08-17 shares, plus long-term 2025-03-31 (15 months older than the period end) plus current 2019-03-31 (88 months older than the period end), minus cash 2019-03-31
Enterprise value CHUC
| FY Dec 2025 | $88.8M |
| FY Dec 2024 | $19.6M |
| FY Dec 2023 | $32.7M |
| FY Dec 2022 | $28.6M |
| FY Dec 2021 | $27.3M |
| Jun 2026 | $65.5M |
| Mar 2026 | $84.7M |
| Dec 2025 | $88.8M |
| Sep 2025 | $95.1M |
| Jun 2025 | $32.3M |
| Mar 2025 | $19.0M |
| Dec 2024 | $19.6M |
| Sep 2024 | $22.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-10.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield CHUC
| FY Dec 2025 | -7.0% |
| FY Dec 2024 | -11.6% |
| FY Dec 2023 | -2.9% |
| FY Dec 2022 | -8.0% |
| FY Dec 2021 | -6.1% |
| Jun 2026 | -7.1% |
| Mar 2026 | -8.3% |
| Dec 2025 | -7.0% |
| Sep 2025 | -7.4% |
| Jun 2025 | -17.0% |
| Mar 2025 | -12.8% |
| Dec 2024 | -11.6% |
| Sep 2024 | -7.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CHUC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $20.9M | $8.5M | $16.2M | $26.4M |
| Gross profit | $5.7M | $2.9M | n/a | n/a |
| Operating income | -$2.2M | -$3.3M | -$2.2M | -$1.8M |
| Net income | $4.5M | -$4.2M | -$2.1M | -$1.6M |
| EPS (diluted) | 0.02 | -0.02 | -0.01 | -0.01 |
| Operating cash flow | -$5.8M | -$1.6M | -$783.0K | -$1.7M |
| Long-term debt | n/a | $2.2M | $2.5M | $1.4M |
| Dividends paid | n/a | n/a | n/a | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
CHUC Stock Sonar score 4/7 axes
Find similar shapesCompareCHUC ranks highest on growth (88th percentile) and risk and compliance (88th), and lowest on financial health (33rd), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
